StockCIK 1549595
Nurix Therapeutics, Inc. (NRIX): Insider Trades and Fund Holdings
In the past 12 months, Nurix Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 5 sales worth $885K; 4 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$885KSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 15, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 15 | Gwenn HansenChief Scientific Officer | ▼ SELL10b5-1 | $36K |
| Oct 14 | Julia P. GregoryDirector | ▼ SELL | $529K |
| Oct 2 | Christine RingGeneral Counsel | ▼ SELL10b5-1 | $134K |
| Sep 2 | Christine RingGeneral Counsel | ▼ SELL10b5-1 | $149K |
| Sep 1 | Gwenn HansenChief Scientific Officer | ▼ SELL10b5-1 | $37K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Gwenn Hansen | Chief Scientific Officer | 0 | $0 | 2 | $73K |
| Julia P. Gregory | Director | 0 | $0 | 1 | $529K |
| Christine Ring | General Counsel | 0 | $0 | 2 | $283K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report NRIX
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 0 | $0 | ▼ Sold out |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →